Javier Terriente

ZeClinics is a biotech providing services to industry & academia

ZeClinics (Barcelona, Spain) is a biopharmaceutical company using zebrafish for screenings of novel chemical molecules. Our business strengths rely on high technical expertise, top-notch research facilities and attractive strategic partnerships and academic collaborations.

Project at ZENITH

Publications

  • Publication 1: Jarque S, Ibarra J, Rubio-Brotons M, García-Fernández J, Terriente J. Multiplex Analysis Platform for Endocrine Disruption Prediction Using Zebrafish. Int J Mol Sci. 2019. Apr 8;20(7).

  • Publication 2: Pant DC, Dorboz I, Schlüter A, Fourcade S, Launay N, Joya J, Aguilera-Albesa S, Yoldi ME, Casasnovas C, Willis MJ, Ruiz M, Ville D, Lesca G, Siquier-Pernet K, Desguerre I, Yan H, Wang J, Burmeister M, Brady L, Tarnopolsky M, Cornet C, Rubbini D, Terriente J, James KN, Musaev D, Zaki MS, Patterson MC, Lanpher BC, Klee EW, Pinto E Vairo F, Wohler E, Sobreira NLM, Cohen JS, Maroofian R, Galehdari H, Mazaheri N, Shariati G, Colleaux L, Rodriguez D, Gleeson JG, Pujades C, Fatemi A, Boespflug-Tanguy O, Pujol A. Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy. J Clin Invest. 2019 Jan 8.

  • Publication 3: Cornet C, Di Donato V, Terriente J#. Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline. Front Pharmacol. 2018 Jul 3.

Contact

IGTP Edifici Muntanya - Carretera de Can Ruti, Camí de les Escoles s/n; 08916 BDN, Lab P-08; Barcelona, SPAIN

Email: hr@zeclinics.com

Website: https://www.zeclinics.com/